Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults.
| Author | |
|---|---|
| Abstract |
:
VRC01 is a human broadly neutralizing monoclonal antibody (bnMAb) against the CD4-binding site of the HIV-1 envelope glycoprotein (Env) that is currently being evaluated in a Phase IIb adult HIV-1 prevention efficacy trial. VRC01LS is a modified version of VRC01, designed for extended serum half-life by increased binding affinity to the neonatal Fc receptor. |
| Year of Publication |
:
2018
|
| Journal |
:
PLoS medicine
|
| Volume |
:
15
|
| Issue |
:
1
|
| Number of Pages |
:
e1002493
|
| ISSN Number |
:
1549-1277
|
| URL |
:
http://dx.plos.org/10.1371/journal.pmed.1002493
|
| DOI |
:
10.1371/journal.pmed.1002493
|
| Short Title |
:
PLoS Med
|
| Download citation |
